KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer

May 29-June 2, 2015; Chicago, Illinois
Median overall survival was 11 months, with a median duration of response of 40 weeks with pembrolizumab in PD-L1–positive gastric cancer.
Format: Microsoft PowerPoint (.ppt)
File Size: 624 KB
Released: June 2, 2015


Educational grant provided by:
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Novartis Pharmaceuticals Corporation

Related Content

John L. Marshall, MD discusses key data in GI malignancies from ASCO 2020 and optimizing therapeutic benefit through management of cancer cachexia

John L. Marshall, MD Released: June 30, 2020

Expert discussion of key results in lung and gastrointestinal cancers from ASCO 2020 reported by CCO, including new agents, new approaches, and supportive care

person default Mary Jo Fidler, MD John L. Marshall, MD Released: June 17, 2020

PRODIGE 23 data from ASCO 2020 on neoadjuvant mFOLFIRINOX plus chemoradiotherapy in T3/T4 rectal cancer, as reported by Clinical Care Options (CCO)

Released: June 5, 2020

Results from RTOG 1010 (trastuzumab plus chemoradiotherapy plus surgery for HER2+ esophageal cancer) from ASCO 2020, as reported by Clinical Care Options (CCO)

Released: June 2, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?